Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme analogue presented as a lyophilized powder for intravenous infusion. It is used to treat acute intermittent porphyria by supplying exogenous heme to patients experiencing porphyria attacks, thereby reducing the buildup of toxic precursors and alleviating neurovisceral symptoms.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality‑controlled distribution, temperature‑managed logistics and regulatory compliance across multiple markets. The company’s global network facilitates rapid delivery to emergency departments and specialized care units.

Normosang is used in the management of porphyria disorders by providing heme to suppress the pathogenic pathway.

Acute intermittent porphyria: reduces neurotoxic porphyrin precursor accumulation and relieves acute attacks. Acute hepatic porphyria: supplies exogenous heme to down‑regulate ALAS activity during symptomatic episodes. Porphyria‑related neurovisceral symptoms: alleviates pain, nausea and autonomic dysfunction associated with attacks.

Human Hemin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever or chills - Nausea or vomiting - Headache - Injection site pain or erythema

Serious or Rare Side Effects: - Hypersensitivity reactions including anaphylaxis - Acute hemolysis in G6PD‑deficient patients - Renal impairment or acute kidney injury

When using Normosang, several precautions should be observed to ensure patient safety.

Dose adjustment: required in patients with hepatic impairment Monitoring: regular assessment of liver function tests during therapy Avoid use: in patients with known hypersensitivity to human hemin or any excipients Pregnancy and lactation: safety not established; use only if benefit outweighs risk Drug interactions: consider potential interaction with enzyme‑inducing agents Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Normosang can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampicin, carbamazepine): may reduce hemin efficacy - Iron supplements: can precipitate with hemin solution - Concurrent use with other heme‑containing products: risk of overdose

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may alter coagulation parameters - Diuretics: monitor renal function - Anticonvulsants: possible alteration of seizure threshold